Clinical Trial Update: Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the investigational HER3-targeting antibody-drug conjugate U3-1402 in HER3-positive metastatic breast cancer has completed enrollme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• U3-1402 (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-13